{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.4","upperLimit":"69.3","value":"57.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Overall response was defined as the best overall confirmed response of: Complete response (CR): Negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \\< 5% plasma cells in bone marrow (BM). Stringent CR (sCR): CR and normal serum free light chain ratio and no clonal cells in BM. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \\< 100 mg/24-h). PR: ≥ 50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \\< 200 mg/24-h. Assessment was by IRC per International Myeloma Working Group Uniform Response Criteria (IMWG-URC). The 90% confidence intervals were estimated using the Clopper-Pearson method (1994).","dispersionType":"90% Confidence Interval","groups":[{"description":"Carfilzomib was administered intravenously on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression or end of study. A dose of 20 mg/m\\^2 was administered on day 1 of cycle 1; all subsequent doses were 56 mg/m\\^2. From cycle 13, the frequency of carfilzomib administration was reduced to days 1 and 15 (± 2 days) per cycle until progression or end of study.\n\nDexamethasone was administered orally or intravenously at a dose of 40 mg on days 1, 8, 15, and 22 of each cycle during cycles 1 to 12, and at a dose of 20 mg on days 1 and 15 from cycle 13 until progression or end of study.\n\nPomalidomide 4 mg was administered orally on days 1 to 21 of each cycle until progression or end of study.","id":"OG000","title":"Carfilzomib With Pomalidomide and Dexamethasone (KPd)"}],"paramType":"NUMBER","populationDescription":"The safety analysis set included all participants who received at least 1 dose of carfilzomib.","reportingStatus":"POSTED","timeFrame":"From day 1 cycle 1 until the primary analysis (PA) data cutoff (DCO); the mean duration of KPd treatment as of the DCO was 42.0 weeks","title":"Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}